{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T01:08:54Z","timestamp":1789434534303,"version":"build-2803163510"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T00:00:00Z","timestamp":1754697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T00:00:00Z","timestamp":1754697600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Ministry of Science and Technology of China","award":["84000-51200002"],"award-info":[{"award-number":["84000-51200002"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81873428"],"award-info":[{"award-number":["81873428"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Sun Yat-sen University Start-up Funding","award":["201603"],"award-info":[{"award-number":["201603"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Cell Int"],"DOI":"10.1186\/s12935-025-03916-6","type":"journal-article","created":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T03:46:10Z","timestamp":1754711170000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Predicting survival of persons with newly-diagnosed multiple myeloma"],"prefix":"10.1186","volume":"25","author":[{"given":"Limei","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert Peter","family":"Gale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,9]]},"reference":[{"key":"3916_CR1","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","volume":"397","author":"N van de Donk","year":"2021","unstructured":"van de Donk N, Pawlyn C, Yong KL. Multiple myeloma. Lancet. 2021;397:410\u201327.","journal-title":"Lancet"},{"key":"3916_CR2","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1001\/jama.2022.0003","volume":"327","author":"AJ Cowan","year":"2022","unstructured":"Cowan AJ, Green DJ, Kwok M, et al. Diagnosis and management of multiple myeloma: A review. JAMA. 2022;327:464\u201377.","journal-title":"JAMA"},{"key":"3916_CR3","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1056\/NEJMra1011442","volume":"364","author":"A Palumbo","year":"2011","unstructured":"Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364:1046\u201360.","journal-title":"N Engl J Med"},{"key":"3916_CR4","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U","volume":"36","author":"BG Durie","year":"1975","unstructured":"Durie BG, Salmon S. E.A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36:842\u201354.","journal-title":"Cancer"},{"key":"3916_CR5","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","volume":"23","author":"PR Greipp","year":"2005","unstructured":"Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23:3412\u201320.","journal-title":"J Clin Oncol"},{"key":"3916_CR6","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised international staging system for multiple myeloma: A report from international myeloma working group. J Clin Oncol. 2015;33:2863\u20139.","journal-title":"J Clin Oncol"},{"key":"3916_CR7","doi-asserted-by":"crossref","unstructured":"Kumar SK, Mikhael JR, Buadi FK et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. Mayo Clin Proc.2009; 84:1095\u20131110.","DOI":"10.4065\/mcp.2009.0603"},{"key":"3916_CR8","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1002\/ajh.24891","volume":"92","author":"H Cho","year":"2017","unstructured":"Cho H, Yoon DH, Lee JB, et al. Comprehensive evaluation of the revised international staging system in multiple myeloma patients treated with novel agents as a primary therapy. Am J Hematol. 2017;92:1280\u20136.","journal-title":"Am J Hematol"},{"key":"3916_CR9","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/leu.2017.179","volume":"32","author":"V Shah","year":"2018","unstructured":"Shah V, Sherborne AL, Walker BA, et al. Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients. Leukemia. 2018;32:102\u201310.","journal-title":"Leukemia"},{"key":"3916_CR10","doi-asserted-by":"publisher","first-page":"3509","DOI":"10.1182\/bloodadvances.2020002218","volume":"4","author":"N Abdallah","year":"2020","unstructured":"Abdallah N, Greipp P, Kapoor P, et al. Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities. Blood Adv. 2020;4:3509\u201319.","journal-title":"Blood Adv"},{"key":"3916_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.arr.2016.08.006","volume":"31","author":"P Soysal","year":"2016","unstructured":"Soysal P, Stubbs B, Lucato P, et al. Inflammation and frailty in the elderly: A systematic review and meta-analysis. Ageing Res Rev. 2016;31:1\u20138.","journal-title":"Ageing Res Rev"},{"key":"3916_CR12","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.amjmed.2009.01.026","volume":"122","author":"ER Wilhelm-Leen","year":"2009","unstructured":"Wilhelm-Leen ER, Hall YN, M K T, Chertow GM. Frailty and chronic kidney disease: the third National health and nutrition evaluation survey. Am J Med. 2009;122:664\u2013e671662.","journal-title":"Am J Med"},{"key":"3916_CR13","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s00277-007-0375-6","volume":"87","author":"I Yavasoglu","year":"2008","unstructured":"Yavasoglu I, Tombuloglu M, Kadikoylu G, Donmez A, Cagirgan S. Bolaman z.cholesterol levels in patients with multiple myeloma. Ann Hematol. 2008;87:223\u20138.","journal-title":"Ann Hematol"},{"key":"3916_CR14","doi-asserted-by":"crossref","unstructured":"Kyle RA, Gertz MA, Witzig TE et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc.2003; 78:21\u201333.","DOI":"10.4065\/78.1.21"},{"key":"3916_CR15","doi-asserted-by":"publisher","first-page":"dju124","DOI":"10.1093\/jnci\/dju124","volume":"106","author":"AJ Templeton","year":"2014","unstructured":"Templeton AJ, McNamara MG, \u0160eruga B, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014;106:dju124.","journal-title":"J Natl Cancer Inst"},{"key":"3916_CR16","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","volume":"20","author":"BG Durie","year":"2006","unstructured":"Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20:1467\u201373.","journal-title":"Leukemia"},{"key":"3916_CR17","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1200\/JCO.2009.25.2114","volume":"28","author":"H Ludwig","year":"2010","unstructured":"Ludwig H, Bolejack V, Crowley J, et al. Survival and years of life lost in different age cohorts of patients with multiple myeloma. J Clin Oncol. 2010;28:1599\u2013605.","journal-title":"J Clin Oncol"},{"key":"3916_CR18","doi-asserted-by":"publisher","first-page":"4039","DOI":"10.1182\/blood-2007-03-081018","volume":"111","author":"H Ludwig","year":"2008","unstructured":"Ludwig H, Durie BG, Bolejack V, et al. Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the international myeloma working group. Blood. 2008;111:4039\u201347.","journal-title":"Blood"},{"key":"3916_CR19","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1007\/s00277-021-04529-5","volume":"100","author":"MJ Cejalvo","year":"2021","unstructured":"Cejalvo MJ, Bustamante G, Gonz\u00e1lez E, et al. Treatment patterns and outcomes in real-world transplant-ineligible patients newly diagnosed with multiple myeloma. Ann Hematol. 2021;100:1769\u201378.","journal-title":"Ann Hematol"},{"key":"3916_CR20","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/s41375-019-0539-0","volume":"34","author":"T Facon","year":"2020","unstructured":"Facon T, Dimopoulos MA, Meuleman N, et al. A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial. Leukemia. 2020;34:224\u201333.","journal-title":"Leukemia"},{"key":"3916_CR21","doi-asserted-by":"publisher","first-page":"e154","DOI":"10.1016\/S2352-3026(18)30220-5","volume":"6","author":"G Cook","year":"2019","unstructured":"Cook G, Royle KL, Pawlyn C, et al. A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK myeloma research alliance risk Profile): a development and validation study. Lancet Haematol. 2019;6:e154\u201366.","journal-title":"Lancet Haematol"},{"key":"3916_CR22","doi-asserted-by":"crossref","unstructured":"Liu X, Xu P, Wang L et al. Cholesterol levels provide prognostic information in patients with multiple myeloma. Clin Lab.2020; 66.","DOI":"10.7754\/Clin.Lab.2019.190824"},{"key":"3916_CR23","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s00280-003-0692-y","volume":"53","author":"VT Hungria","year":"2004","unstructured":"Hungria VT, Latrilha MC, Rodrigues DG, Bydlowski SP, Chiattone CS, Maranh\u00e3o. R c.metabolism of a cholesterol-rich microemulsion (LDE) in patients with multiple myeloma and a preliminary clinical study of LDE as a drug vehicle for the treatment of the disease. Cancer Chemother Pharmacol. 2004;53:51\u201360.","journal-title":"Cancer Chemother Pharmacol"},{"key":"3916_CR24","first-page":"2359","volume":"74","author":"R Scolozzi","year":"1983","unstructured":"Scolozzi R, Boccafogli A, Salmi R, et al. [Hypocholesterolemia in multiple myeloma. Inverse relation to the component M and the clinical stage]. Minerva Med. 1983;74:2359\u201364.","journal-title":"Minerva Med"},{"key":"3916_CR25","doi-asserted-by":"crossref","unstructured":"Krejcik J, Barnkob MB, Nyvold CG, Larsen TS, Barington T. Abildgaard n.harnessing the immune system to fight multiple myeloma. Cancers (Basel).2021; 13.","DOI":"10.3390\/cancers13184546"},{"key":"3916_CR26","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1158\/1078-0432.CCR-19-2111","volume":"26","author":"AD Cohen","year":"2020","unstructured":"Cohen AD, Raje N, Fowler JA, Mezzi K, Scott EC, Dhodapkar MV. How to train your T cells: overcoming immune dysfunction in multiple myeloma. Clin Cancer Res. 2020;26:1541\u201354.","journal-title":"Clin Cancer Res"},{"key":"3916_CR27","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1054\/bjoc.1999.1012","volume":"82","author":"P Garnero","year":"2000","unstructured":"Garnero P, Buchs N, Zekri J, Rizzoli R, Coleman RE, Delmas PD. Markers of bone turnover for the management of patients with bone metastases from prostate cancer. Br J Cancer. 2000;82:858\u201364.","journal-title":"Br J Cancer"},{"key":"3916_CR28","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/bjh.15837","volume":"186","author":"H Miki","year":"2019","unstructured":"Miki H, Nakamura S, Oura M, et al. Correlation between high serum alkaline phosphatase levels and denosumab-related hypocalcemia in patients with multiple myeloma. Br J Haematol. 2019;186:355\u20138.","journal-title":"Br J Haematol"},{"key":"3916_CR29","doi-asserted-by":"crossref","unstructured":"Geng C, Yang G, Wang H, Zhang Z, Zhou H, Chen W. The prognostic role of prothrombin time and activated partial thromboplastin time in patients with newly diagnosed multiple myeloma. Biomed Res Int.2021; 2021:6689457.","DOI":"10.1155\/2021\/6689457"},{"key":"3916_CR30","doi-asserted-by":"publisher","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","volume":"4","author":"NC Munshi","year":"2020","unstructured":"Munshi NC, Avet-Loiseau H, Anderson KC, et al. A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. Blood Adv. 2020;4:5988\u201399.","journal-title":"Blood Adv"},{"issue":"1","key":"3916_CR31","doi-asserted-by":"publisher","first-page":"2338604","DOI":"10.1080\/07853890.2024.2338604","volume":"56","author":"Q Li","year":"2024","unstructured":"Li Q, Ai L, Zuo L, et al. Circulating plasma cells as a predictive biomarker in multiple myeloma: an updated systematic review and meta-analysis. Ann Med. 2024;56(1):2338604.","journal-title":"Ann Med"}],"container-title":["Cancer Cell International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-025-03916-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12935-025-03916-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-025-03916-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T19:50:19Z","timestamp":1757361019000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancerci.biomedcentral.com\/articles\/10.1186\/s12935-025-03916-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,9]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3916"],"URL":"https:\/\/doi.org\/10.1186\/s12935-025-03916-6","relation":{},"ISSN":["1475-2867"],"issn-type":[{"value":"1475-2867","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,9]]},"assertion":[{"value":"23 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Institutional Review Board and Ethics Committee of Sun Yat-sen University Cancer Center and was exempted from the need for informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The authors have obtained consent to publish from the participant to report patient data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"301"}}